Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update
Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (NASDAQ:YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update…